<p>Regorafenib is a kinase inhibitor that is indicated:</p>

<ul>
	<li>For the treatment of metastatic colorectal cancer (CRC) after disease progression on or intolerance to fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy.</li>
	<li>For the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) after disease progression on or intolerance to prior treatment with imatinib and sunitinib.</li>
	<li>For the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib</li>
</ul>